We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings
Read MoreHide Full Article
Key Takeaways
{\"0\":\"Edwards Lifesciences will report Q3 2025 results on Oct. 30, after market close.\",\"1\":\"EW\'s TAVR sales are projected at $1.11B, up 8.5% year over year on SAPIEN 3 Ultra RESILIA strength.\\r\\n\",\"2\":\"EW\'s TMTT revenues are estimated to surge 47.2% to $134.1M, led by PASCAL and EVOQUE traction.\"}
Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report third-quarter 2025 results on Oct. 30, after market close.
In the last reported quarter, the company’s adjusted earnings per share of 67 cents beat the Zacks Consensus Estimate by 8.06%. Its earnings beat estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 5.50%.
EW’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.50 billion, suggesting 11.5% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings of 59 cents per share indicates an 11.9% decline from the year-ago reported figure.
Estimate Revision Trend Ahead of Edwards’ Q3 Earnings
Estimates for earnings have remained unchanged at 59 cents per share in the past 30 days.
Here’s a brief overview of the company’s progress ahead of this announcement.
Factors at Play
In the third quarter of 2025, the Transcatheter Aortic Valve Replacement (“TAVR”) arm is likely to have delivered a strong performance in the United States, thanks to its market-leading SAPIEN 3 Ultra RESILIA platform. The continued expansion of SAPIEN3 Ultra RESILIA in Europe is expected to have supported the international performance. The platform has demonstrated remarkable patient outcomes, and the momentum is expected to have continued with more centers adopting it. Third-quarter sales in Japan are expected to have improved.
Edwards has raised its 2025 sales growth guidance for this segment to 6-7% (earlier 5% to 7%), and we expect the company to have progressed meaningfully in the to-be-reported quarter. Our model assumes TAVR sales to be $1.11 billion, implying an 8.5% year-over-year increase.
In the Transcatheter Mitral and Tricuspid Therapies (“TMTT”) segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards’ performance in third-quarter 2025. The PASCAL repair system is expected to have gained traction in the United States, Europe and globally, thanks to its differentiated features, leading to increased adoption of the technology at both existing and new centers.
Additionally, the commercial launch of the EVOQUE tricuspid replacement system might have continued to progress in the United States and Europe. Also, with the addition of SAPIEN M3, Edwards is uniquely positioned to meet the broad and diverse needs of patients with mitral and tricuspid valve diseases.
Our model estimates the TMTT business to report revenues of $134.1 million, implying a 47.2% improvement from the year-ago period’s level.
Edwards Lifesciences Corporation Price and EPS Surprise
Lastly, Edwards’ Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT. Additionally, KONECT received CE Mark approval in Europe during the previous quarter, which might have contributed to the third-quarter top line.
Our model estimates the segment’s revenues to be $256.7 million, suggesting a modest 7% rise from the year-ago quarter’s reported figure.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of +0.47%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some other medical stocks worth considering, as these too have the right combination of elements to post an earnings beat this time around:
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +32.65% and a Zacks Rank #1 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
EXAS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 329.87%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is expected to increase 147.6% from the year-ago quarter's figure.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +1.15% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2025 results soon.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%. Per the Zacks Consensus Estimate, ANIP’s third-quarter EPS is expected to surge 29.9% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.23% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
IDXX’s earnings topped estimates in each of the trailing four quarters, the average surprise being 6.08%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is anticipated to increase 12.1% from the year-ago quarter figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings
Key Takeaways
Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report third-quarter 2025 results on Oct. 30, after market close.
In the last reported quarter, the company’s adjusted earnings per share of 67 cents beat the Zacks Consensus Estimate by 8.06%. Its earnings beat estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 5.50%.
EW’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.50 billion, suggesting 11.5% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings of 59 cents per share indicates an 11.9% decline from the year-ago reported figure.
Estimate Revision Trend Ahead of Edwards’ Q3 Earnings
Estimates for earnings have remained unchanged at 59 cents per share in the past 30 days.
Here’s a brief overview of the company’s progress ahead of this announcement.
Factors at Play
In the third quarter of 2025, the Transcatheter Aortic Valve Replacement (“TAVR”) arm is likely to have delivered a strong performance in the United States, thanks to its market-leading SAPIEN 3 Ultra RESILIA platform. The continued expansion of SAPIEN3 Ultra RESILIA in Europe is expected to have supported the international performance. The platform has demonstrated remarkable patient outcomes, and the momentum is expected to have continued with more centers adopting it. Third-quarter sales in Japan are expected to have improved.
Edwards has raised its 2025 sales growth guidance for this segment to 6-7% (earlier 5% to 7%), and we expect the company to have progressed meaningfully in the to-be-reported quarter. Our model assumes TAVR sales to be $1.11 billion, implying an 8.5% year-over-year increase.
In the Transcatheter Mitral and Tricuspid Therapies (“TMTT”) segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards’ performance in third-quarter 2025. The PASCAL repair system is expected to have gained traction in the United States, Europe and globally, thanks to its differentiated features, leading to increased adoption of the technology at both existing and new centers.
Additionally, the commercial launch of the EVOQUE tricuspid replacement system might have continued to progress in the United States and Europe. Also, with the addition of SAPIEN M3, Edwards is uniquely positioned to meet the broad and diverse needs of patients with mitral and tricuspid valve diseases.
Our model estimates the TMTT business to report revenues of $134.1 million, implying a 47.2% improvement from the year-ago period’s level.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote
Lastly, Edwards’ Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT. Additionally, KONECT received CE Mark approval in Europe during the previous quarter, which might have contributed to the third-quarter top line.
Our model estimates the segment’s revenues to be $256.7 million, suggesting a modest 7% rise from the year-ago quarter’s reported figure.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of +0.47%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Top MedTech Picks
Here are some other medical stocks worth considering, as these too have the right combination of elements to post an earnings beat this time around:
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +32.65% and a Zacks Rank #1 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
EXAS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 329.87%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is expected to increase 147.6% from the year-ago quarter's figure.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +1.15% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2025 results soon.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%. Per the Zacks Consensus Estimate, ANIP’s third-quarter EPS is expected to surge 29.9% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.23% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
IDXX’s earnings topped estimates in each of the trailing four quarters, the average surprise being 6.08%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is anticipated to increase 12.1% from the year-ago quarter figure.